Behind Closed Doors: Funding New Medical Product Ideas
Published Date: 3/17/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on April 14, 2025, to review secret grant applications for new product development. This meeting affects researchers seeking funding and keeps sensitive info private. No public access means the focus is on protecting ideas and personal details while deciding who gets money.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Closed NIH Review Protects Applicants' Secrets
The National Institute of Allergy and Infectious Diseases will hold a closed meeting on April 14, 2025 (10:00 a.m. to 1:30 p.m.) to review and evaluate grant applications for the R34 Planning for Product Development Strategy. The meeting is closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets or patentable material and personal information of individuals associated with the applications.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-17438, Center For Scientific Review; Notice of Closed Meetings
The NIH's Center for Scientific Review is holding several closed virtual meetings in late September 2026 to review and evaluate grant applications. These meetings protect private info and trade secrets, affecting researchers applying for funding. No direct money changes are announced, but these reviews decide who gets research grants.
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
Previous / Next Documents
Previous: 2025-04251, National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting
The National Institute of Allergy and Infectious Diseases is holding a closed video meeting on May 8, 2025, to review special grant applications. This meeting affects researchers applying for funding and keeps sensitive info private. No public access or clinical trials are involved, but important funding decisions will be made.
Next: 2025-04253, National Institute on Drug Abuse; Notice of Closed Meetings
The National Institute on Drug Abuse is holding two secret virtual meetings in April 2025 to review grant applications for new treatments and research on drug use and HIV. These closed meetings protect private info and trade secrets while deciding who gets funding. Scientists and organizations applying for grants should watch for these important review dates that could impact future research money.